Abstract 3223: Novel tubulin inhibitor DJ101 targets the colchicine binding site and suppresses melanoma growth and metastasis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3223
Abstract: Interfering with microtubule dynamics is a validated approach for anticancer treatment and by selectively targeting the colchicine binding site on tubulin, microtubule destabilizing agents can evade mechanisms of drug resistance that commonly develop with other… read more here.
Keywords: tubulin; binding site; tubulin inhibitor; colchicine binding ... See more keywords
Abstract 4943: SP-1-39 as a novel tubulin inhibitor overcomes taxane resistance in castration-resistant prostate cancer model
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4943
Abstract: Colchicine binding site inhibitors have proven to have potent anti-cancer efficacy in many cancer types. Inhibition of tubulin polymerization, a popular mechanism of action for anti-cancer activities, will be activated once the inhibitor interacts with… read more here.
Keywords: tubulin inhibitor; prostate cancer; cancer;
S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16050749
Abstract: Microtubule-targeting agents are widely used as active anticancer drugs. However, drug resistance always emerges after their long-term use, especially in the case of paclitaxel, which is the cornerstone of all subtypes of breast cancer treatment.… read more here.
Keywords: paclitaxel resistance; breast cancer; tubulin inhibitor; cancer ... See more keywords